Kabir A. Khan

1.6k total citations · 2 hit papers
21 papers, 1.2k citations indexed

About

Kabir A. Khan is a scholar working on Molecular Biology, Immunology and Allergy and Oncology. According to data from OpenAlex, Kabir A. Khan has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Immunology and Allergy and 5 papers in Oncology. Recurrent topics in Kabir A. Khan's work include Angiogenesis and VEGF in Cancer (11 papers), Cell Adhesion Molecules Research (6 papers) and Protease and Inhibitor Mechanisms (3 papers). Kabir A. Khan is often cited by papers focused on Angiogenesis and VEGF in Cancer (11 papers), Cell Adhesion Molecules Research (6 papers) and Protease and Inhibitor Mechanisms (3 papers). Kabir A. Khan collaborates with scholars based in United Kingdom, Canada and India. Kabir A. Khan's co-authors include Robert S. Kerbel, Roy Bicknell, Michael G. Tomlinson, Fiyaz Mohammed, Peter J. Noy, Schickwann Tsai, Paloma García, Jing Yang, Dion Morton and Florence T.H. Wu and has published in prestigious journals such as Journal of Biological Chemistry, Oncogene and The FASEB Journal.

In The Last Decade

Kabir A. Khan

21 papers receiving 1.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

2018 479 citations Kabir A. Khan, Robert S. Kerbel Nature Reviews Clinical Oncology profile →
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials

2024 47 citations Kabir A. Khan, Robert S. Kerbel et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kabir A. Khan United Kingdom	15	547	489	320	217	199	21	1.2k
Amy Ziober United States	20	467 0.9×	418 0.9×	233 0.7×	189 0.9×	200 1.0×	39	1.2k
Eleni Maniati United Kingdom	19	580 1.1×	750 1.5×	708 2.2×	272 1.3×	155 0.8×	40	1.6k
Fotis Asimakopoulos United States	20	538 1.0×	557 1.1×	333 1.0×	194 0.9×	92 0.5×	40	1.3k
Huocong Huang United States	18	493 0.9×	803 1.6×	464 1.4×	254 1.2×	114 0.6×	33	1.3k
Marjo Hahka‐Kemppinen Finland	18	545 1.0×	651 1.3×	220 0.7×	198 0.9×	122 0.6×	33	1.1k
Lee B. Rivera United States	15	626 1.1×	853 1.7×	499 1.6×	343 1.6×	197 1.0×	22	1.6k
Molly A. Taylor United States	18	970 1.8×	624 1.3×	432 1.4×	510 2.4×	146 0.7×	30	1.7k
Yvonne T.M. Tsang United States	18	533 1.0×	329 0.7×	166 0.5×	211 1.0×	141 0.7×	24	1.2k
Surabhi Dangi‐Garimella United States	14	749 1.4×	673 1.4×	200 0.6×	426 2.0×	82 0.4×	34	1.4k
Evangeline Mose United States	18	563 1.0×	551 1.1×	283 0.9×	239 1.1×	105 0.5×	25	1.2k

Countries citing papers authored by Kabir A. Khan

Since Specialization

Citations

This map shows the geographic impact of Kabir A. Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kabir A. Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kabir A. Khan more than expected).

Fields of papers citing papers by Kabir A. Khan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kabir A. Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kabir A. Khan. The network helps show where Kabir A. Khan may publish in the future.

Co-authorship network of co-authors of Kabir A. Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Kabir A. Khan. A scholar is included among the top collaborators of Kabir A. Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kabir A. Khan. Kabir A. Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khan, Kabir A., et al.. (2024). Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nature Reviews Clinical Oncology. 21(6). 468–482. 47 indexed citations breakdown →

Lewis, Jonathan J., Jason D. Turner, Isaac Dean, et al.. (2024). Type-H endothelial cell protein Clec14a orchestrates osteoblast activity during trabecular bone formation and patterning. Communications Biology. 7(1). 1296–1296. 1 indexed citations

Huijbers, Elisabeth J. M., Kabir A. Khan, Robert S. Kerbel, & Arjan W. Griffioen. (2022). Tumors resurrect an embryonic vascular program to escape immunity. Science Immunology. 7(67). eabm6388–eabm6388. 41 indexed citations

Khan, Kabir A., Madeleine Benguigui, Ping Xu, et al.. (2020). Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. npj Breast Cancer. 6(1). 29–29. 28 indexed citations

Khan, Kabir A. & Robert S. Kerbel. (2020). A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis. EMBO Molecular Medicine. 12(6). e12355–e12355. 7 indexed citations

Khan, Kabir A., et al.. (2019). C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation. FEBS Journal. 286(17). 3299–3332. 61 indexed citations

Khan, Kabir A. & Robert S. Kerbel. (2018). Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nature Reviews Clinical Oncology. 15(5). 310–324. 479 indexed citations breakdown →

Wu, Florence T.H., Ping Xu, Annabelle Chow, et al.. (2018). Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. British Journal of Cancer. 120(2). 196–206. 39 indexed citations

Zuo, Jianmin, Carrie R. Willcox, Fiyaz Mohammed, et al.. (2017). A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding. Science Signaling. 10(481). 23 indexed citations

10.

Khan, Kabir A., Amy J. Naylor, Abdullah O. Khan, et al.. (2017). Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface. Oncogene. 36(44). 6097–6108. 55 indexed citations

11.

Noy, Peter J., et al.. (2016). Sprouting angiogenesis is regulated by shedding of the C‐type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid‐like 2 protein (RHBDL2). The FASEB Journal. 30(6). 2311–2323. 29 indexed citations

12.

Khan, Kabir A. & Roy Bicknell. (2015). Anti-angiogenic alternatives to VEGF blockade. Clinical & Experimental Metastasis. 33(2). 197–210. 24 indexed citations

13.

Noy, Peter J., Kabir A. Khan, Xiaodong Zhuang, et al.. (2015). Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene. 34(47). 5821–5831. 43 indexed citations

14.

Sreenivas, A., Anthony Harries, Srinath Satyanarayana, et al.. (2012). Are all patients diagnosed with tuberculosis in Indian medical colleges referred to the RNTCP? [Short communication]. The International Journal of Tuberculosis and Lung Disease. 16(8). 1083–1085. 3 indexed citations

15.

Haining, Elizabeth J., Jing Yang, Kabir A. Khan, et al.. (2012). The TspanC8 Subgroup of Tetraspanins Interacts with A Disintegrin and Metalloprotease 10 (ADAM10) and Regulates Its Maturation and Cell Surface Expression. Journal of Biological Chemistry. 287(47). 39753–39765. 121 indexed citations

16.

Herbert, John, et al.. (2011). The emerging role of tetraspanin microdomains on endothelial cells. Biochemical Society Transactions. 39(6). 1667–1673. 60 indexed citations

17.

Khan, Kabir A., et al.. (2006). Desmocollin switching in colorectal cancer. British Journal of Cancer. 95(10). 1367–1370. 72 indexed citations

18.

Brukner, Peter, Kabir A. Khan, & Kevin P. Singer. (2006). Thoracic and Chest Pain. UWA Profiles and Research Repository (UWA). 340–350. 2 indexed citations

19.

Khan, Kabir A., Tengbin Xiong, Ian McCafferty, et al.. (2005). Extracolonic findings at CT colonography an a symptomatic population (oral abstract). 1 indexed citations

20.

Khan, Kabir A., et al.. (2000). Hemangiopericytoma of greater omentum.. PubMed. 19(1). 33–33. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact